E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 9/23/2005 in the Prospect News Biotech Daily.

New Issue: Acusphere prices $18.72 million follow on offering at $5.25, discounted from $5.93 close

By Ronda Fears

Nashville, Sept. 23 - Acusphere Inc. priced an offering of 3,566,000 shares of its common stock at $5.25 each, discounted from the close Thursday at $5.93, via bookrunner Piper Jaffray & Co.

Based in Watertown, Mass., Acusphere has three product candidates in clinical development in the areas of cardiology, oncology and asthma. Its lead candidate, AI-700, is in phase III clinical development for the detection of coronary artery disease.

Issuer:Acusphere Inc.
Issue:Follow-on stock offering
Gross proceeds:$18,721,500
Net proceeds:$17.5 million
Shares:3,566,000
Price:$5.25 per share
Bookrunner:Piper Jaffray & Co.
Pricing date:Sept. 22
Settlement date:Sept. 28
Ticker:ACUS
Stock price:$5.93 at close Sept. 22

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.